Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Durect ( (DRRX) ) just unveiled an update.
On July 28, 2025, DURECT Corporation entered into a merger agreement with Bausch Health Americas, Inc., where Bausch will acquire DURECT for $1.75 per share in cash, with potential additional milestone payments. This acquisition, expected to close in the third quarter of 2025, will bolster Bausch Health’s commitment to hepatology and liver disease treatments, particularly with the promising development of Larsucosterol for alcoholic hepatitis, a condition with no current FDA-approved treatments. The merger reflects strategic alignment and potential value for stakeholders, enhancing Bausch Health’s portfolio in liver disease therapeutics.
The most recent analyst rating on (DRRX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Durect stock, see the DRRX Stock Forecast page.
Spark’s Take on DRRX Stock
According to Spark, TipRanks’ AI Analyst, DRRX is a Underperform.
Durect’s overall stock score reflects significant financial difficulties, weak technical indicators, and negative valuation metrics. The most impactful factor is the company’s financial instability, which is compounded by technical weakness and valuation concerns. The potential delisting adds further risk.
To see Spark’s full report on DRRX stock, click here.
More about Durect
DURECT Corporation is a late-stage biopharmaceutical company focused on developing epigenetic therapies to address serious and life-threatening conditions, including acute organ injury. Their lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy Designation, aimed at treating alcoholic hepatitis.
Average Trading Volume: 109,387
Technical Sentiment Signal: Sell
Current Market Cap: $17.16M
See more data about DRRX stock on TipRanks’ Stock Analysis page.